We propose the mechanism of cyclophosphamide-induced methemoglobinemia to resemble the one reported on the ifosfamide case, since they share similar chemical compounds, metabolic pathways, and ...

Cyclophosphamide is widely used to treat severe manifestations of ... targeting the fibrotic mechanisms have not been developed despite the increased understanding of the key pathogenic pathways.

Other effective therapies targeting the fibrotic mechanisms have not been developed despite the increased understanding of the key pathogenic pathways. The two pivotal studies of cyclophosphamide in ...

Publisher's Note. The December 1, 2006 article by Jones et al entitled, "Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for ...

PURPOSEInfluences of adjuvant epirubicin/cyclophosphamide (EC) chemotherapy on blood coagulation were investigated in patients with operable breast cancer and the incidence of thromboembolic events ...

SAN DIEGO — Although fading from use in vasculitis management strategies, cyclophosphamide still offers several benefits for a minority of patients who are unable to switch to other therapies ...

Cyclophosphamide improved skin, global and muscle symptoms related to juvenile dermatomyositis when used as a second-line treatment, with no short-term side effects, according to findings ...

They all had cyclophosphamide as part of their treatment. How much cyclophosphamide the children had depended on: their height and weight; the treatment schedule for their cancer Between the children ...

Rituximab and cyclophosphamide are equally effective in achieving remission or low disease activity rates in childhood-onset antineutrophil cytoplasmic antibody–associated vasculitis (AAV), and ...

Meeting Coverage > ACR Safer Alternative to Cyclophosphamide at Hand for ILD? — Drug targeting B cells as effective as broad-spectrum immunosuppressant in lung disease ...